Journal article icon

Journal article

Cancer cell lines for drug discovery and development.

Abstract:

Despite the millions of dollars spent on target validation and drug optimization in preclinical models, most therapies still fail in phase III clinical trials. Our current model systems, or the way we interpret data from them, clearly do not have sufficient clinical predictive power. Current opinion suggests that this is because the cell lines and xenografts that are commonly used are inadequate models that do not effectively mimic and predict human responses. This has become such a widesprea...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology, Molecular Medicine
Role:
Author
Publisher:
American Association for Cancer Research Inc.
Journal:
Cancer research
Volume:
74
Issue:
9
Pages:
2377-2384
Publication date:
2014-05-05
DOI:
EISSN:
1538-7445
ISSN:
0008-5472
URN:
uuid:c13b5bde-eb39-4db8-93bd-86e5b306e536
Source identifiers:
462318
Local pid:
pubs:462318

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP